Dermatology - Page 6
The MD Magazine Dermatology - Page 6 specialty page provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Diagnosing Plaque Psoriasis a 'Straightforward' Effort for Dermatologists
With plaque psoriasis becoming an increasingly common condition providers are able to more easily identify the condition than they had in the past. Looking for red scaling plaques, and thickened skin, as well as asking questions can get doctors the answers they need. In rare cases skin biopsies are also performed.
The days of patients with plaque psoriasis being treated with tar and special lights are fading as new agents, especially oral agents, are being developed.
Proactive administration of topical corticosteroid was found to reduce allergen sensitization in patients with atopic dermatitis (AD) as well as the periodic exacerbation of pruritic eczema.
It appears that 300 mg of omalizumab (Xolair/Genentech) is effective in reducing angioedema, according to the results of a new study.
For many patients, chronic idiopathic urticaria can be a debilitating condition affecting them at all hours of the day and making living with the condition very difficult. Because of this, the need for newer, more effective treatments is driving the field forward at a rapid pace.
When a patient is diagnosed with chronic idiopathic urticaria, there are several things doctors can do to help them. The process to get the proper diagnosis can take several weeks, which can complicate the situation for patients.
People can experience bouts of urticaria over the course of their lives, but usually they only last for a matter of days. When the symptoms last six weeks or more, it can be classified as chronic idiopathic urticaria.
Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.
A review of studies concludes that switching psoriatic arthritis patients who have stopped responding to one tumor necrosis factor inhibitor (TNFi) to another will likely reduce their symptoms, but the effectiveness of each new medication will likely be less than each former medication.

Most Popular in Dermatology - Page 6

Recent Published Journal


$vacMongoViewPlus$ $vAR$